DEPRESSIVE DISORDERS AND THEIR CORRECTION IN PATIENTS WITH COMPLICATED DIABETIC FOOT SYNDROME

Abstract

Abstract. The aim of the study. To assess the frequency and expressiveness of depressive disorder in patients with complicated SDS, as well as the effectiveness of pharmacotherapy with venlafaxine in this contingent of individuals.
 Materials and methods. A comprehensive clinical and psychopathological examination of 270 patients for complicated diabetic foot syndrome (DFS) was conducted for the period 2019–2022.
 Results. All patients were operated on, an autopsy and drainage of a purulent-necrotic foci of the foot or amputation at different levels was performed. The average age of the patients was (64,2 ± 2,3) years. The average duration of diabetes was (12,4 ± 1,6) years. Depressive disorders were detected in 169 patients, which made up 62,6 % of the total group, including 106 women (62,7 %) and 63 men (37,3 %). To evaluate the effectiveness of psychopharmacotherapy of depressive disorders, patients were divided into two groups. Patients of the control group (n = 84) received standard therapy (local treatment of wounds, antibacterial, infusion, disaggregant and vascular therapy, analgesia, correction of glycemia). Patients in the main group (n = 85) were prescribed venlafaxine (Venlafaxine) in a dose of 75–150 mg in the morning during meals, for 3 months, along with standard therapy. Psychopathological examination was carried out during hospitalization, on the 20–21st day of treatment and 3 months after the start of therapy. In the control group (standard therapy), depressive disorder did not undergo a significant (P>0,05) improvement.
 Conclusions. The conducted course of psychopharmacotherapy of depressive disorders in patients with complicated SDS had a significant effect, both in terms of the manifestations of depression itself (Р<0.05), and in improving the quality of life of patients (Р<0.05). Treatment with venlafaxine made it possible to reduce the manifestations of depression already on the 20–21st day of treatment. The reduction of depressive symptoms was most clearly recorded 3 months after the start of therapy.